“Mitochondria are responsible for producing the energy needed to support and regulate the body’s cell growth and function.”
This newsletter is made possible from the generous contributions of MUSC’s neurosciences faculty and staff. The success of this publication is dependant upon this support. Thank you for your interest, time and information. For inquiries, suggestions or submission information please contact Emma C. Vought, MS (vought@musc.edu).

TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairs’ Message</td>
<td>1</td>
</tr>
<tr>
<td>Events</td>
<td>2</td>
</tr>
<tr>
<td>Foundation</td>
<td>3</td>
</tr>
<tr>
<td>News</td>
<td>4-8</td>
</tr>
<tr>
<td>Publications</td>
<td>9</td>
</tr>
<tr>
<td>Clinical Trials</td>
<td>10-15</td>
</tr>
<tr>
<td>Grants</td>
<td>16-17</td>
</tr>
<tr>
<td>Employee Update</td>
<td>18-19</td>
</tr>
<tr>
<td>Social News</td>
<td>20</td>
</tr>
</tbody>
</table>

© 2012 Medical University of South Carolina. All rights reserved.
Dear Readers,

As the end of summer quickly approaches, there are many new and exciting developments in the Department of Neurosciences.

Joining our team this year are several new faculty and staff. Among them is Bruce Ovbiagele, M.D., MSc, who we are pleased to announce is our new Chair of Neurology. He will be joining our team on September 1, 2012. Along with impressive training and credentials, his background includes a faculty position at the UCLA Department of Neurology in 2002, where he served as Director of the Olive View-UCLA Medical Center Stroke Program, Director of the UCLA Stroke PROTECT Program, and Supervisor of the Vascular Neurology Residency at Olive View-UCLA Medical Center. In 2011, he joined the faculty of the University of California San Diego (UCSD) as Professor of Neurosciences and was appointed Director of the San Diego Veteran Affairs Medical Center Stroke Program. He is a member of various medical associations, and an active researcher. His research portfolio includes funding from the NIH, and the American Heart Association.

Looking back over the past few months, it is important to recognize the work that is done within our department to raise awareness and funds for a variety of neurological diseases. One such example is "The Liví Center for Neurometabolic and Mitochondrial Medicine," which is being established in memory of Miss Oliva "Liví" Custer, a brave little girl who suffered from Leigh’s Disease, a form of mitochondrial disease. Also, our Stroke Team continues to raise awareness each year by participating in ‘National Go Red Day,’ as well as other awareness events that took place in Spring 2012. Finally, we celebrated our 5th year of raising awareness and funds for brain tumor research through the MUSC Brain & Spine Tumor Program’s growing list of events that are held each May, which is known nationally as Brain Tumor Awareness Month. These brain tumor awareness and education events continue to grow each year and this year we raised more funds than ever, totaling over $20,000 thanks to the hard work of our volunteers and supporters. You can find more detailed information on each of these within this newsletter.

In the news: we are thrilled to announce that we received 2011-2012 Higher Performance recognition for Neurology and Neurosurgery by US News and World Reports Best Hospital, with the Medical University of South Carolina ranking as #1 hospital in South Carolina.

We would like to thank our faculty and staff for all of their continued hard work and commitment, and we look forward to the start of a new educational year and welcome our new residents, fellows and graduate students!

---

Bruce Ovbiagele, M.D., MSc, Chair of Neurology, Department of Neurosciences

Education:
Univ. of Lagos: Doctor of Medicine (M.D.)
Univ. of CA, Los Angeles: Master of Science (MSc) in Clinical Research
Univ. of CA, San Diego: Master of Advanced Studies (MAS) in Leadership of Healthcare Systems

Clinical Training:
Los Angeles County/King-Drew Medical Center: Dual Internships in Psychiatry and Internal Medicine, 1996-1998
Univ. of CA, Irvine Medical Center: Residency in General Neurology, 1998-2001
Univ. of CA, Los Angeles, Medical Center: Fellowship in Vascular Neurology, 2001-2002

Board Certified:
American Board of Psychiatry and Neurology: General Neurology 2004
American Board of Psychiatry and Neurology: Vascular Neurology 2005
Certifying Commission in Medical Management: Medical Management 2011
Neurosciences Featured Events

AUGUST 27, 2012 - NEUROSCIENCE INSTITUTE MEET & GREET
Each year the Neuroscience Institute hosts a Meet & Greet Reception to welcome new Ph.D. students interested in a Neuroscience degree. This gives MUSC’s new students the opportunity to meet other students, postdoctoral scholars, residents, fellows, and faculty from MUSC who they will be working with, as well as neuroscientists from the College of Charleston. For more information call 843-792-2392.

SEPTEMBER (DATE TBA) - STUDENT INTEREST GROUP IN NEUROLOGY (SIGN) ACTIVITY FAIR

SEPTEMBER 22, 2012 - WALK TO END ALZHEIMER’S
The Alzheimer’s Research and Clinical Programs (ARCP) offers free Alzheimer’s education and presentations at various community events. These events include health fairs, church seminars, Alzheimer’s support groups, and more. Topics include: Latest Alzheimer’s Research, Alzheimer’s Tutorial, Myth vs. Fact, Caregiver Stress Tips, and more. Additionally, we conduct community memory screens. For more information contact Marie Corbin (843-740-1592 or corbinm@musc.edu).

SEPTEMBER 29, 2012 - AMERICAN HEART WALK
Join or donate to a MUSC Neurosciences Heart Walk Team. Proceeds go to the American Heart Association. For more information contact Emma Vought (vought@musc.edu).

OCTOBER (DATE TBA) - SECOND ANNUAL DODGEBALL TOURNAMENT STUDENT INTEREST GROUP IN NEUROLOGY (SIGN)

OCTOBER 26, 2012 - NEUROPALOOZA
The Neuroscience Institute has partnered with the Howard Hughes Medical Institute to bring the yearly student/postdoc retreat titled Neuropalooza. Initiated in 2009, this annual all day event includes opportunities to meet and interact with students and postdocs from College of Charleston and MUSC. In addition, an outside plenary speaker and several students/postdocs give talks throughout the day with lunch and refreshments provided. For more information call 843-792-2392.

OCTOBER 29-31, 2012 - 5TH CONFERENCE CLINICAL TRIALS ON ALZHEIMER’S DISEASE, MONTE CARLO
The aims of this International Conference are to bring together the current leaders involved in clinical trials on Alzheimer’s Disease to discuss new results, drugs in development and future methodological issues.

NOVEMBER 3, 2012 - SAVE THE DATE! CLINICAL PEARLS IN MOVEMENT DISORDERS
This event will take place at the Crowne Plaza Hotel in Charleston, SC, and will cover Clinical Pearls in Movement Disorders with DBS programming and botulinum toxin injection breakout sessions. For more information contact the MUSC Office of CME at 843-876-1925 or www.MUSC.edu/cme.

To find out more about Neurosciences events visit:
www.MUSC.edu/neurosciences/events
The Livi Center

Our friends and neighbors, John Wendell Smith and Wendy Smith of Myrtle Beach, recently lost their beloved 3-year-old daughter Jessica following a lifelong struggle with Alpers’ Disease, a rare degenerative mitochondrial disease.

Following Jessica’s courageous fight, the Smiths committed themselves to raising awareness about mitochondrial diseases to help improve the diagnosis and prognosis of patients stricken by them. Toward this end, they have dedicated themselves to helping create the Livi Center at the Medical University of South Carolina.

We ask you to help us support the Smiths in their mission to help create the MUSC Livi Center. We are honored to assist in this effort and hope that you will partner with us in making the Livi Center a reality.

On behalf of the Smith family and all those who suffer from mitochondrial diseases, we thank you for your consideration.

What Is Mitochondrial Disease?
Mitochondria are responsible for producing the energy needed to support and regulate the body’s cell growth and function. When they become diseased, cells become injured and can die. If the process continues unchecked, entire systems begin to fail, greatly compromising and even threatening the life of the person affected.

Who Is Affected?
It primarily affects children, but it is becoming increasingly common among adults. More than 1 in 4,000 children born in the United States each year will develop a mitochondrial disease by age 10.

More Research is Needed
Currently, there is no reliable way to diagnose and treat these rare disorders, but the Medical University of South Carolina is now seeking to establish a center dedicated to finding new treatments and ultimately a cure for them: The Livi Center for Neurometabolic and Mitochondrial Medicine.

The center is being established in memory of Miss Oliva “Livi” Custer, a brave little girl from Beaufort who suffered from Leigh’s Disease, a form of mitochondrial disease. We honor her legacy of strength in the face of adversity by working to find a cure for this devastating disorder and others like it.

How You Can Help
This center will require additional researchers, nurses and physicians that we cannot support with our available resources. Therefore, we are now turning to people like you to make this center a reality. In honor of children like Liv and Jessica, who are in need of this specialized care, we hope that you will assist us in this important cause.

To make a gift or receive more information, please contact:

Debbie Bordeau,
Director of Development for Neurosciences at MUSC
Phone: 843-792-4342, toll-free 800-810-MUSC
Email: bordeau@musc.edu

www.MUSC.edu/neurosciences/gifts
Neurobiology of Addiction Research Center (NARC)

President of the American College of Neuropsychopharmacology
Dr. Peter Kalivas has been elected as President of the American College of Neuropsychopharmacology, this is an honorific organization with national meeting and strong presence in public policy related to drug development, neuropsychiatric disease research and care. He will be acting president for 2013-14.

Dr. Peter Kalivas Honored for Strides Made in Drug and Alcohol Research
Peter Kalivas, Ph.D., professor and co-chair of the Department of Neurosciences, received the South Carolina Governor’s Award for Excellence in Scientific Research while attending the S.C. Academy of Science Annual Meeting on April 14, 2012. Kalivas was recognized for his scientific discoveries regarding drug addiction and serving as an academic leader and department chair in the Medical University of South Carolina (MUSC) College of Medicine for more than a decade. Kalivas’ work contributed to a significant rise in national stature as a leading medical research institution.

“Peter is highly deserving of this award, and we are fortunate to have a scientist of his caliber focused on translating basic science discoveries into clinical interventions for drug addiction, which is a significant problem for South Carolina and the nation as a whole,” said MUSC College of Medicine Dean Etta Pisano, M.D. “In large part due to Dr. Kalivas’ leadership during the last decade, South Carolina now harbors one of the top-tier addiction and neuroscience research organizations in the country.”

Drug addiction in South Carolina is estimated to cost the state $2.5 billion a year in medical treatment, judicial system/incarceration and lost work hours, and in 2005 addiction was directly responsible for the death of 21,932 South Carolinians.

Kalivas and a team of researchers at MUSC receive approximately $15 million in research funding from the National Institutes of Health (NIH) each year to make basic scientific discoveries and translate these findings into clinical trials for addicts. For example, his discovery of the role played by glutamate in addiction has led to testing new treatments in cigarette, marijuana, cocaine, and soon in alcohol addicted citizens of South Carolina.

Kalivas received his Ph.D. in Pharmacology from the University of Washington in 1980 and completed postdoctoral studies at the University of North Carolina at Chapel Hill in 1982. Following faculty appointments at Louisiana State University Medical Center and Washington State University, where he served as Director of the Alcohol and Drug Abuse Program, he joined the faculty at the Medical University of South Carolina in 1998 as professor and chair of the Department of Physiology and Neuroscience. His publication record reflects 293 peer-reviewed papers, serves on many editorial boards and has received numerous honors and awards throughout his career. He also holds a patent, with another pending patent.

~ article from the MUSC news blog

To find out more about NARC visit:
www.MUSC.edu/neurosciences/research
Study May Transform Approach to Patient Selection for Minimally Invasive Stroke Treatment.

San Diego, CA – July 23, 2012 – Study results presented at the Society of Neurointerventional Surgery (SNIS) 9th Annual Meeting show that patients presenting with ischemic stroke may be successfully treated with endovascular therapy well beyond the 4.5 hour treatment window today considered standard by most neurointerventional practitioners. The multicenter study, evaluated the use of computed tomography (CT) perfusion imaging, regardless of time from symptom onset, in selecting patients for endovascular treatment, a technique which utilizes devices or clot-busting drugs directly at the problem site in the brain to disperse clots and restore blood flow. CT perfusion imaging is used in combination with other imaging techniques to determine which areas of the brain are irreversibly injured from a stroke, and which areas are still alive, but at great risk.

Study data collected from the Medical University of South Carolina (MUSC) in Charleston, Swedish Medical Center in Denver, Colorado and the University of Florida in Gainesville, showed that out of 247 patients for whom perfusion imaging was used, 42.5% showed a 90-day modified Rankin Scale score (a measure of the degree of disability in people who have suffered a stroke) of 0 – 2% (considered a good functional outcome), which is comparable to results from all other significant trials to date which evaluated endovascular therapy conducted under eight hours. Notably, this latest study showed no significant difference in treatment outcome between patients treated under eight hours (42.8%) and those treated over eight hours (41.9%). Additionally, immediately following treatment, restoration of blood flow was accomplished in 76% of patients, with a higher success rate in those treated over eight hours (81.1%) as opposed to those treated under eight hours (71.7%). All study subjects underwent mechanical thrombectomy, or treatment utilizing devices to re-open the affected vessel.

“This is truly a landmark study in that it definitively shows that perfusion imaging as a patient selection criteria for endovascular therapy is a successful evaluation tool, whether patients are presenting at three hours out from their stroke or 11 hours,” said Aquilla Turk, D.O., of MUSC. “Broadly speaking, these results could transform our approach to patient selection and ultimately may mean that we will be able to treat significantly more patients and reduce the devastating burden of this disease on individuals and families.”

Study data was collected from 2007 to 2011 from patients with a mean age of 65.9 presenting with an average score of 18 on the NIH Stroke Scale (NIHSS), a standardized measure used to clinically evaluate the degree of impairment of a stroke in such areas as consciousness, vision, speech, movement, language and sensation. Anyone with an NIHSS score of less than 8 was excluded from the study. The overall mean time from symptom onset to treatment start was 4.8 hours for those treated within eight hours and 16.4 for those treated over eight hours. The mortality rate for study subjects was 23%.

Currently, neurointerventional practitioners primarily use devices to restore blood flow in stroke patients as they can more immediately disperse the clot while drugs often take time to dissolve the occlusion and pose the added risks of bleeding. Treatment with devices is accomplished by maneuvering the instrument through a catheter inserted into the groin area and threaded through the arteries to the site of the clot. The first device, the Merci Retriever, was introduced in 2004 and since that time, multiple devices have made their way into the neurointerventionist’s treatment arsenal.

~ SOURCE Society of NeuroInterventional Surgery
MUSC Stroke Center News

Awards/Recognitions:
• February 2, 2012 – ISC, New Orleans, Louisiana - Palmetto Gold Award: Medical Center winner Perette Sabatino, R.N., BSN, Stroke Program Manager is a medical center nursing leader who was selected for the distinguished Palmetto Gold award. Each year 100 nurse professionals throughout the state are selected as Palmetto Gold recipients for their excellence in nursing practice and commitment to the profession.

February 6, 2012 – Edward Jauch, M.D., “Letter of Appreciation”, was recognized for his leadership as Board Director from the American Heart Association at the International Stroke Conference, New Orleans, LA.

February 22, 2012 – Robert J. Adams, M.D. was recognized by Castle Connolly as one of America’s Top Doctors. This signals that the quality of his medical work is highly regarded by his fellow physicians and that he is widely considered to be outstanding in his field.

May 2012 - Andrea Boan, Ph.D. Candidate was awarded the Young Investigator-in-Training Abstract Competition Presenter at the American Society of Hypertension Annual Conference held in New York City.

Welcome Students
We welcome these students who have been selected to participate in the Summer Health Professional Program working under the direction of Daniel Lackland, DrPH, Robert J. Adams, MS, MD and the Stroke Center Team. This summer course provides professional students with the opportunity to work with a faculty member on a funded research project and acquaints the students with an area of specialized research currently under investigation in the faculty member’s laboratory.

Community Events
February 3, 2012 - National Go Red Day!
Perette Sabatino, RN, Stroke Program Manager set-up an information table for Community Stroke Education, MUSC Stroke Program Awareness and Risk Factor Screening.

February 18, 2012 - Tri-County Community Health and Wellness Fair
Sponsored by the Tri-County Black Nurses Association, Perette Sabatino, RN, Stroke Program Manager had an MUSC Stroke Program Booth at this event for:
- Stroke Education for the community
- Stroke Program awareness for the community
- Screening for risk factors for stroke was provided to the public

March 15, 2012 - Community Engaged Assessment to Eliminate Stroke (CEASE, PI Dr. Jauch):
The first Georgetown Community Advisory board for Stroke meeting was held Thursday March 15, 2012 at the Georgetown County Public Library, Georgetown, SC.

Neuroscience Institute (NI) Update

NI Frontiers
Each year, the Neuroscience Institute at MUSC hosts a research day consisting of lectures and poster presentations from labs all over the state. The event includes a nationally recognized keynote speaker as well as six presentations by scientists and/or physicians from MUSC or other South Carolina institutions. The lectures provide the latest information on cutting-edge basic brain and behavioral science relating to the chosen theme. This allows physicians to apply the most up-to-date research available for the diagnosis and treatment of their patients.

This year’s Frontiers in Neuroscience Research Day conference was held on March 30, 2012 at the Seabrook Island Club. The theme for the event was “Neurodegenerative Disorders”. Dr. Gary Aston-Jones, Director of the Neuroscience Institute, welcomed 150 researchers, clinicians, educators, and students. In his opening remarks, Dr. Aston-Jones gave a financial update, the past progress and the future direction of the Neuroscience Institute.

Dr. Richard Palmiter, from the University of Washington, gave the keynote address titled “Genetic Approaches for Studying the Roles of Dopamine and Glutamate Signaling in the Basal Ganglia”. Dr. Palmiter is Professor of Biochemistry and Adjunct Professor of Genome Sciences at the University of Washington School of Medicine, and among his many honors, he is a member of the National Academy of Sciences. Dr. Palmiter is a leading expert in transgenic and knockout strategies to understand neurotransmitter signaling and behavioral functions.

Local speakers included DeAnna Adkins, Ph.D., Craig Crosson, Ph.D., Kumar Sambamurti, Ph.D., Vanessa Hinson, M.D., Ph.D., Stefanie Kuchinsky, Ph.D., and Joseph Helpern, Ph.D., all from MUSC. Each gave a presentation in their area of expertise, and focused on their current medical research. Questions were addressed at the end of each session.

A highlight of the conference was the afternoon poster session, when everyone got a chance to examine and discuss the 40 research posters developed by professors, residents, postdoctoral fellows, and students. The posters elicited some great conversations, and were all highly competitive for poster prizes awarded each year. First prize was awarded to Joseph Taylor, M.D./Ph.D. Student and Graduate Assistant at MUSC. Second prizes were co-awarded to Jennifer Kaufling.

Trainee Fellowship Awards
The Neuroscience Institute is proud to announce and congratulate the 2012 International Trainee Fellowship Awards. These NI awards provide support to the best trainees at MUSC, who, because of their foreign status, are not eligible for NRSA support.

This year’s recipients are:

Noam Keren, Ph.D. student. The goal of Noam’s research is to establish a framework for reliable imaging of locus coeruleus structure and function in humans and animals.

Adrien Schramm, Postdoctoral Fellow. Adrien’s project is to determine the number and distribution of synapses (or dendritic branches) that need to be lost, e.g., in neurodegenerative disease, in order to compromise single-cell response amplitude or selectivity.

Yonatan M. Kupchik, Postdoctoral Fellow. The goal of Yonatan’s research is to investigate the mechanism by which opiate receptors regulate activity of ventral pallidum neurons.

Andrea Bari, Postdoctoral Fellow. Andrea’s research will elucidate the role of the locus coeruleus-norepinephrine system in response inhibition.

Congratulations are also extended to Elena Vazey, Ph.D. Elena won a renewal on her fellowship from the Parkinson’s Disease Foundation, and therefore she declined her NI Fellowship award this year. Her project is to determine the role of the locus coeruleus brain norepinephrine system in the cognitive deficits that occur in early Parkinson’s Disease.

Congratulations to All!
U.S. News Ranks MUSC

The Medical University of South Carolina (MUSC) has been named by U.S. News & World Report as one of the country’s best hospitals (top 50) in the treatment of ear/nose/throat disorders, nephrology, cardiology and heart surgery, and gastroenterology.

This is the 16th consecutive year for gastroenterology to be ranked. MUSC is also “high-performing” in treating cancer, gynecologic disorders, orthopedics and rheumatology. Programs for diabetes and endocrinology, neurology and neurosurgery, pulmonology, geriatrics and urology also were considered high-performing. Fewer than 150 of the nation’s 5,000 hospitals are nationally ranked in at least one of 16 medical specialties. To see MUSC scores and rankings, go to http://health.usnews.com/best-hospitals/medical-university-of-south-carolina-6370085.

http://www.musc.edu/pr/usnwr2012_best_hospitals.htm

Neurosciences Research Day

The Department of Neurosciences organizes an annual “Neurosciences Research Day”. It is an initiative to promote academic research among the residents and the faculty. The residents and fellows of Neurology and Neurosurgery participate by presenting research projects. Faculty experts from the divisions of neurosurgery, neurology and basic neurosciences judge these presentations and award the participants.

This Year’s Results: May 3rd, 2012

Roland Hamilton, Jr., M.D. - Best Case Report
Nolan Williams, M.D. - Most Promising New Finding
Sylvia Klineova, M.D. - Best Research in Neurology
Libby Kosnik Infinger, M.D. - Best Research in Neurosurgery
Vibhor Krishna, M.D. - Best Overall Presentation

To view the abstracts from Neurosciences Research Day, or to find out more about this event visit: www.MUSC.edu/neurosciences/events

BTAM Wrap Up

Brain Tumor Action Month (BTAM) 2012 was a great success! Events ranged from educational lectures and fair to a benefit concert featuring talented local musicians. Overall these events raised over $20,000! The money raised will go to MUSC Brain Tumor Research. We would like to extend our gratitude to all of those who volunteered their time and efforts towards these events, and those who have supported us with financial contributions. We look forward to planning BTAM 2013, and hope for your continued support.

If you are interested in learning more about these events, becoming a volunteer, or discussing future events please contact Rachel Beard (beardr@musc.edu). Please visit the Medical University of South Carolina Neurosciences facebook page to view photos from all the events.

http://www.facebook.com/pages/Medical-University-of-South-Carolina-Neurosciences/256374294385967?sk=wall

Senior Mentor Program

The Senior Mentor Program is a volunteer program that connects medical students from the Medical University of South Carolina with people, aged 65 and older, living in the greater Charleston, SC area.

Goals:

• To encourage medical students to have positive attitudes about caring for older adults
• To help reduce stereotypes about aging
• To improve the way future doctors care for older patients

Responsibilities:

• We ask that you mentor a pair of MUSC medical students throughout the 4 years of school
• Meet in your home with your students 2-3 times per year to complete assignments
• Agree to share information about yourself with the students
• Give feedback and personal comments to the students

For more information or to receive an application call 843-792-0712 or email dillonk@musc.edu.
Featured Publications


Lazaridis C, Smielewski P, Steiner LA, Brady KM, Hutchinson PJ, Pickard JD, Czosnyka M. **“Optimal Cerebral Perfusion Pressure: Are We Ready For it?”** Neu Res-In Press


http://dx.doi.org/10.1016/j.clineuro.2012.01.037

Publication Highlight:

**Preliminary observations on the vasomotor responses to electrical stimulation of the ventrolateral surface of the human medulla.**
Sunil Patel, Vibhor Krishna, Joyce Nicholas, Charles M Welzig, Cristian Vera

**ABSTRACT:** Object Pulsatile arterial compression (AC) of the ventrolateral medulla (VLM) is hypothesized to produce the hypertension in a subset of patients with essential hypertension. In animals, a network of subpial neuronal aggregates in the VLM has been shown to control cardiovascular functions. Although histochemically similar, neurons have been identified in the retro-olivary sulcus (ROS) of the human VLM, but their function is unclear. Methods The authors recorded cardiovascular responses to electrical stimulation at various locations along the VLM surface, including the ROS, in patients who were undergoing posterior fossa surgery for trigeminal neuralgia. This vasomotor mapping of the medullary surface was...

Illustration by E. C. Vought.

This article is available in the July 2012 issue of The Journal of Neurosurgery www.thejns.org.
## Clinical Trials

The Following Neurosciences Clinical Trials are Actively Enrolling Subjects
(Alzheimer’s, Spine, Movement Disorders, Epilepsy, Neuro-Oncology)

### Alzheimer’s Clinical Trials

<table>
<thead>
<tr>
<th>Title</th>
<th>Sponsor</th>
<th>Principal Investigator</th>
<th>Study Coordinator</th>
<th>Contact/ Phone/ Email</th>
</tr>
</thead>
</table>
| ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE - 2  
To examine how brain imaging technology can be used with other tests to measure the progression of Mild Cognitive Impairment (MCI) and early Alzheimer’s Disease. | National Institute on Aging | Jacobo Mintzer M.D., M.B.A. David Bachman M.D. | Arthur Williams | Marie Corbin 843-740-1592 ext. 14 corbinm@musc.edu |
| CERE - 110  
To evaluate the potential benefits of CERE-110 in the treatment of Alzheimer’s Disease. CERE-110 is an experimental drug that is designed to help nerve cells in the brain function better. | National Institute on Aging and Ceregene, Inc. | Jacobo Mintzer M.D., M.B.A. David Bachman M.D. | Arthur Williams | Marie Corbin 843-740-1592 ext. 14 corbinm@musc.edu |
| BAPINEZUMAB - 3000  
To evaluate the efficacy and safety of multiple doses of bapinezumab in patients with mild to moderate Alzheimer’s Disease who are not carriers of the APOE 4 gene. | Pfizer Pharmaceuticals | Jacobo Mintzer M.D., M.B.A. David Bachman M.D. | Joanne Rose, RN | Marie Corbin 843-740-1592 ext. 14 corbinm@musc.edu |
| CITAD  
To study the effectiveness of citalopram for reducing agitation in people with Alzheimer’s Disease. | National Institute of Health | Jacobo Mintzer M.D., M.B.A. David Bachman M.D. | Nicholas Gregory | Marie Corbin 843-740-1592 ext. 14 corbinm@musc.edu |
| RES  
To evaluate the impact on biomarkers of resveratrol treatment in patients with mild to moderate Alzheimer’s Disease. | Alzheimer’s Disease Cooperative Study and National Institute on Aging | Jacobo Mintzer M.D., M.B.A. David Bachman M.D. | Nicholas Gregory | Marie Corbin 843-740-1592 ext. 14 corbinm@musc.edu |

To find out more about clinical trials at MUSC visit:

www.MUSC.edu/TRU
<table>
<thead>
<tr>
<th><strong>MOVEMENT DISORDERS CLINICAL TRIALS</strong></th>
<th><strong>SPONSOR</strong></th>
<th><strong>PRINCIPAL INVESTIGATOR</strong></th>
<th><strong>STUDY COORDINATOR</strong></th>
<th><strong>CONTACT/PHONE/EMAIL</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CD PROBE - Cervical Dystonia - Patient Registry for Observation of Botox® Efficacy (CD-PROBE)</td>
<td>Allergan Sales, LLC</td>
<td>Vanessa Hinson, M.D., Ph.D.</td>
<td>Jennifer Zimmerman, RN</td>
<td>Jennifer Zimmerman, RN 843-792-9115 <a href="mailto:zimmerj@musc.edu">zimmerj@musc.edu</a></td>
</tr>
<tr>
<td>Parkinson’s Disease Neuroprotection Clinical Trial Center - FS Zone Supplemental Study (FS Zone)</td>
<td>NIH/NINDS</td>
<td>Vanessa Hinson, M.D., Ph.D.</td>
<td>Jennifer Zimmerman, RN</td>
<td>Jennifer Zimmerman, RN 843-792-9115 <a href="mailto:zimmerj@musc.edu">zimmerj@musc.edu</a></td>
</tr>
<tr>
<td>A Phase II, multi-centre, randomized, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane™ (PYM50028), a novel, orally active neurotrophic factor inducer, in male and female subjects with early-stage Parkinson’s disease when administered once daily for 28 weeks. (Phytopharm)</td>
<td>Phytopharm Plc (ICON Clinical Research)</td>
<td>Gonzalo Revuelta, D.O.</td>
<td>Jennifer Zimmerman, RN</td>
<td>Jennifer Zimmerman, RN 843-792-9115 <a href="mailto:zimmerj@musc.edu">zimmerj@musc.edu</a></td>
</tr>
<tr>
<td>A double-blind, randomized, placebo-controlled study of the safety and efficacy of SYN115 as adjunctive therapy in levodopa-treated Parkinson’s subjects with end of dose wearing off (Synosia)</td>
<td>Synosia Therapeutics, Inc.</td>
<td>Gonzalo Revuelta, D.O.</td>
<td>Jennifer Zimmerman, RN</td>
<td>Jennifer Zimmerman, RN 843-792-9115 <a href="mailto:zimmerj@musc.edu">zimmerj@musc.edu</a></td>
</tr>
<tr>
<td>Creatine Safety, Tolerability, and Efficacy in Huntington’s Disease: CREST-E (Crest-E)</td>
<td>Massachusetts General Hospital</td>
<td>Gonzalo Revuelta, D.O.</td>
<td>Amy DeLambo, ACNP</td>
<td>Amy DeLambo, ACNP 843-792-7262 <a href="mailto:delambo@musc.edu">delambo@musc.edu</a></td>
</tr>
</tbody>
</table>

Clinical trials are the primary way breakthroughs in treating diseases are made.
### The KIVA™ System

As part of the KAST trial, you will have imaging studies (MRI, DXA and X-ray) to evaluate the fractures in your back and your bone health. These procedures are commonly used in patients who have broken back bones whether you are on the study or not. The procedure can be done under local or general anesthesia – your doctor will determine which option is best for you. The procedure usually takes less than an hour per fracture treated and you may be required to stay in the hospital overnight if your doctor determines it is necessary.

For more information on the KAST clinical trial call 843-792-9016.

#### The Kiva Implant

The Kiva Implant is designed to:

- **Utilize** a single incision to access the broken back bone
- **Require** a small amount of bone cement to set the fracture
- **Preserve** the structure of the natural bone in the vertebral body
- **Potentially reduce** the rate of subsequent fractures in the back compared to other similar procedures

Comparison of a typical lumbar vertebral section (left) and section with a compression fracture (right). Illustrations created by E. C. Vought.
# Neuro-Oncology Clinical Trials

<table>
<thead>
<tr>
<th>Title</th>
<th>Sponsor</th>
<th>Principal Investigator</th>
<th>Study Coordinator</th>
<th>Contact Phone/Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diffusion: Protocol # 100-202 Open-Label Phase I/2 (Safety Lead-In) Study of Trans Sodium Crocetinate (TSC) with Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy</td>
<td>Translational Research Unit (TRU)/ Diffusion Pharmaceuticals LLC</td>
<td>Pierre Giglio, M.D. Tel: 843-792-6592</td>
<td>Michele DeCandio, RN</td>
<td>Michele DeCandio, RN Tel: 843-792-9016 E-mail: <a href="mailto:decandio@musc.edu">decandio@musc.edu</a></td>
</tr>
<tr>
<td>BTTC 11-01 Randomized, Double-Blind Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade Gliomas</td>
<td>Clinical Trials Office (Hollings Cancer Center)/ BTTC (Brain Tumor Trials Collaborative)</td>
<td>Pierre Giglio, M.D. Tel: 843-792-6592</td>
<td>Michele DeCandio, RN</td>
<td>Michele DeCandio, RN Tel: 843-792-9016 E-mail: <a href="mailto:decandio@musc.edu">decandio@musc.edu</a></td>
</tr>
<tr>
<td>Protocol CDX110-04: ‘An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The “Act IV” Study)</td>
<td>Translational Research Unit (Neurosciences)/ Cellnex Therapeutics</td>
<td>Bruce Frankel, M.D. Tel: 843-792-1470</td>
<td>Michele DeCandio, RN</td>
<td>Michele DeCandio, RN Tel: 843-792-9016 E-mail: <a href="mailto:decandio@musc.edu">decandio@musc.edu</a></td>
</tr>
<tr>
<td>Glioblastoma, Recurrent: CTO: 101482 RTOG 0929: Randomized Phase I/II Study OF ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma</td>
<td>Clinical Trials Office (Hollings Cancer Center)/ RTOG 0929</td>
<td>Pierre Giglio, M.D. Tel: 843-792-6592</td>
<td>John Keller</td>
<td>John Keller Tel: 843-792-1286 E-mail: <a href="mailto:kellej@musc.edu">kellej@musc.edu</a></td>
</tr>
<tr>
<td>The Efficacy of PF-02341066 (Crizotinib), a Dual ALK/c-Met Inhibitor in Inhibiting Growth of Glioblastoma</td>
<td>Translational Research Unit (TRU)/Pfizer</td>
<td>Pierre Giglio, M.D. Tel: 843-792-6592 Arabinda Das, Ph.D. E-mail: <a href="mailto:dasa@musc.edu">dasa@musc.edu</a></td>
<td>Michele DeCandio, RN</td>
<td>Michele DeCandio, RN Tel: 843-792-9016 E-mail: <a href="mailto:decandio@musc.edu">decandio@musc.edu</a></td>
</tr>
<tr>
<td>The Effect of Garlic Compounds on Fresh Human Glioma Biopsies: CTO: 101378</td>
<td>Translational Research Unit (Neurosciences)</td>
<td>Arabinda Das, Ph.D. E-mail: <a href="mailto:dasa@musc.edu">dasa@musc.edu</a></td>
<td>Michele DeCandio, RN</td>
<td>Michele DeCandio, RN Tel: 843-792-9016 E-mail: <a href="mailto:decandio@musc.edu">decandio@musc.edu</a></td>
</tr>
<tr>
<td>Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment with Bevacizumab for Progressive Disease</td>
<td>Clinical Trials Office (Hollings Cancer Center)/HCC Translational Research Grant</td>
<td>Pierre Giglio, M.D. Tel: 843-792-6592 Joseph Helpern, Ph.D. E-mail: <a href="mailto:helpern@musc.edu">helpern@musc.edu</a></td>
<td>John Keller</td>
<td>John Keller Tel: 843-792-1286 E-mail: <a href="mailto:kellej@musc.edu">kellej@musc.edu</a></td>
</tr>
<tr>
<td>Trial Description</td>
<td>Sponsor/Institution</td>
<td>Contact Person(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anaplastic Glioma, Adjuvant (1):</strong></td>
<td>Clinical Trials Office (Hollings Cancer Center) / The CATNON Intergroup Trial (RTOG 834)</td>
<td>Pierre Giglio, M.D. Tel: 843-792-6592 John Keller</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTo: 101450 RTOG EORTC 0834/26053 22054, “Phase III Trial on concurrent and adjuvant temozolomide chemotherapy in Non-1p/19q deleted anaplastic glioma.”</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>A Phase II Clinical Trial Evaluating DCVax®-brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme</strong></td>
<td>Translational Research Unit (Neurosciences) / Northwest Biotherapeutics, Inc.</td>
<td>Pierre Giglio, M.D. Tel: 843-792-6592 Michele DeCandio, RN Tel: 843-792-9016</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Anaplastic Glioma, Adjuvant (2):</em></td>
<td>Clinical Trials Office (Hollings Cancer Center) / NCCTG</td>
<td>Pierre Giglio, M.D. Tel: 843-792-6592 John Keller</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTo: 101449 Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with Ip/19q Codeleted Anaplastic Glioma*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Low Grade Glioma, Progressive:</strong></td>
<td>Clinical Trials Office (Hollings Cancer Center) / ECOG (Study E3F05); RTOG Endorsed</td>
<td>Pierre Giglio, M.D. Tel: 843-792-6592 John Keller</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTo: 101399 ECOG E3F05, “Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas.”</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DCVax® Clinical Trial**

“A Phase II Clinical Trial Evaluating DCVax® Brain, Autologous dendritic Cells Pulsed with Tumor lysate Antigen for the Treatment of Glioblastoma Multiforme” proposes to study the potential efficacy of a “vaccine” developed by exposing immune cells obtained from patients with glioblastoma with a lysate from the tumor obtained at surgery for tumor resection.

- Pierre Giglio, M.D.

For more information on this trial call 843-792-9016.

A stylized illustration of a t-cell being activated by a dendritic cell. Image created by E. C. Vought.
## Epilepsy Clinical Trials

<table>
<thead>
<tr>
<th>Title</th>
<th>Sponsor</th>
<th>Principal Investigator</th>
<th>Study Coordinator</th>
<th>Contact Phone/Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel-group Study with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic-Clonic Seizures</td>
<td>Eisai</td>
<td>Jonathan Halford, M.D.</td>
<td>Ashley Gantt</td>
<td>843-792-7118 <a href="mailto:gantt@musc.edu">gantt@musc.edu</a></td>
</tr>
<tr>
<td>The purpose of this study is to compare the effectiveness of Gamma Knife radiosurgery with temporal lobectomy in the treatment of patients with pharmaco-resistant mesial temporal lobe epilepsy.</td>
<td>University of California, San Francisco</td>
<td>Ekrem Kutluay, M.D.</td>
<td>Ashley Gantt</td>
<td>843-792-7118 <a href="mailto:gantt@musc.edu">gantt@musc.edu</a></td>
</tr>
<tr>
<td>This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200 mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.</td>
<td>UCB, Inc.</td>
<td>Jonathan Halford, M.D.</td>
<td>Ashley Gantt</td>
<td>843-792-7118 <a href="mailto:gantt@musc.edu">gantt@musc.edu</a></td>
</tr>
<tr>
<td>The purpose of the study is to assess the safety and tolerability of intravenous (IV) carbamazepine (CBZ) administered as multiple 15 minute infusions to adult patients with epilepsy on stable higher doses of oral CBZ. (CARBAMAZEPINE - IV)</td>
<td>Lundbeck, Inc</td>
<td>Jonathan Halford, M.D.</td>
<td>Ashley Gantt</td>
<td>843-792-7118 <a href="mailto:gantt@musc.edu">gantt@musc.edu</a></td>
</tr>
<tr>
<td>A prospective, open-label study of the structure and function of the retina in adult patients with refractory complex partial seizures treated with vigabatrin (Sabril®) (Lundbeck Vision)</td>
<td>Lundbeck, Inc</td>
<td>Ekrem Kutluay, M.D.</td>
<td>Ashley Gantt</td>
<td>843-792-7118 <a href="mailto:gantt@musc.edu">gantt@musc.edu</a></td>
</tr>
</tbody>
</table>

They shed light on new ways to detect, diagnose and reduce risk of disease.
## Research Awards: March 2012 - May 2012

<table>
<thead>
<tr>
<th>PI</th>
<th>Title, Agency, Award #</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adkins, D</td>
<td>Cortical Stimulation to Enhance Motor Recovery Following Traumatic Brain Injury PA NIH/NINDS 7 R01 NS065866-02 (12050581)</td>
<td>$177,386</td>
</tr>
<tr>
<td>Cason, A</td>
<td>PACD Scholar: Dr. Angie Cason, Univ. of South Carolina 5 P20 RR016461-11 (12010075)</td>
<td>$19,159</td>
</tr>
<tr>
<td>Frankel, B</td>
<td>ACT IV (An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed Surgically Resected EGFRvIII-Positive GBM) Novella Clinical, Inc. CDX110-04 (12091267)</td>
<td>$164,583</td>
</tr>
<tr>
<td>Kindy, M</td>
<td>Lowcountry Partnership for Biomedical Innovation, Coll. of Charleston IIP-0917987 (11032907)</td>
<td>$34,487</td>
</tr>
<tr>
<td>Mintzer, J</td>
<td>Alzheimer’s Disease Neuroimaging Initiative, Univ. of California, San Diego AG024904 (11021159)</td>
<td>$279,750</td>
</tr>
<tr>
<td>Ramamoorthy, S</td>
<td>Kappa-Opioid Receptor Mediated Regulation of Dopamine Transport, NIH/NIMH 5 R01 MH083928-03 (12081127)</td>
<td>$328,722</td>
</tr>
<tr>
<td>Turner, R</td>
<td>EV3 Training Event (2/26/12 and 2/27/12), ev3 Neurovascular Training event (12081123)</td>
<td>$25,205</td>
</tr>
<tr>
<td>Turner, R</td>
<td>Prevention of Photoparoxysmal Abnormalities Through Patterned Auditory Stimulation, MIND Institute (12081180)</td>
<td>$46,000</td>
</tr>
<tr>
<td>Walker, A</td>
<td>Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment, Aga Medical Corp. RESPECT (04101301)</td>
<td>$317,822</td>
</tr>
</tbody>
</table>

### MARCH 2012

<table>
<thead>
<tr>
<th>PI</th>
<th>Title, Agency, Award #</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adams, R</td>
<td>TWiTCH (Transcranial Doppler with Tranfusions Changing to Hydroxyurea) Baylor Univ. 101522883/R01 HL095647-03 (11032592)</td>
<td>$122,244</td>
</tr>
<tr>
<td>Adams, R</td>
<td>SMARTSTATE Stroke Endowed Chair MUSC Fdn. (12081037)</td>
<td>$106,979</td>
</tr>
<tr>
<td>Buhusi, C</td>
<td>Attentional Processing of Temporal Information NIH/NIMH 5 R01 MH065651-09 (12013344)</td>
<td>$292,050</td>
</tr>
<tr>
<td>Cook, J</td>
<td>Role of PPAR gamma and PPAR gamma Agonists in Septic Shock Childrens Hospital Research Fdn. 104972 M4/R01 GM067202-08 (11051629)</td>
<td>$60,000</td>
</tr>
<tr>
<td>Giglio, P</td>
<td>Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with Malignant Gliomas Univ. of Texas MD Anderson Cancer Center BTTC11-01 (12081104)</td>
<td>$20,000</td>
</tr>
<tr>
<td>Kalivas, P</td>
<td>Glutamate and Craving for Cocaine, NIH/NIDA 5 R01 DA12513-13 (12091248)</td>
<td>$304,034</td>
</tr>
<tr>
<td>Riegel, Jr, A</td>
<td>Relapse to Cocaine-Seeking: Cellular Adaptations in the Ventral Tegmental Area NIH/NIDA 1 R01 DA033542-01 (11120240)</td>
<td>$295,000</td>
</tr>
<tr>
<td>Smith, R</td>
<td>Molecular Mechanisms of Cocaine-Induced Alterations in Accumbens AMPA Receptors NIH/NIDA 5 F32 DA031919-02 (12070901)</td>
<td>$46,260</td>
</tr>
<tr>
<td>Voeks, J</td>
<td>Carotid Revascularization Endarterectomy vs. Stenting Trial: Long Term Follow-Up Univ. of Alabama, Birmingham R01NS038384 (12091314)</td>
<td>$100,250</td>
</tr>
</tbody>
</table>

### APRIL 2012

---

**NI Poster Printing**

Just $33 base rate plus $1 per linear foot

[www.MUSC.edu/neuroscienceinstitute](http://www.MUSC.edu/neuroscienceinstitute)
## Research Awards Continued...

<table>
<thead>
<tr>
<th>Researcher</th>
<th>Grant Title</th>
<th>Institution</th>
<th>Bibliography</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adkins, D</td>
<td>Cortical Stimulation to Enhance Motor Recovery Following Traumatic Brain Injury NIH/NINDS 5R01NS065866-03 (12101384)</td>
<td></td>
<td></td>
<td>$253,040</td>
</tr>
<tr>
<td>Aston-Jones, G</td>
<td>Role of Extended Amygdala in Opiate and Cocaine Abuse NIH/ NIDA 5R37DA006214-24 (12101378)</td>
<td></td>
<td></td>
<td>$425,194</td>
</tr>
<tr>
<td>Aston-Jones, G</td>
<td>Role of Locus Coeruleus in Response Inhibition NIH/NIMH 5R01MH092868-02 (12101379)</td>
<td></td>
<td></td>
<td>$331,875</td>
</tr>
<tr>
<td>Chandler, L</td>
<td>Actin-Dynamics and Spine Remodeling in Ethanol-Induced Plasticity NIH/NIAAA 5R01AA010983-15 (12101436)</td>
<td></td>
<td></td>
<td>$335,355</td>
</tr>
<tr>
<td>Chimowitz, M</td>
<td>Biomarkers of Ischemic Outcomes in Symptomatic Intracranial Stenosis (BIOSIS) Emory Univ. S443002/R01NS064162 (12101421)</td>
<td></td>
<td></td>
<td>$9,543</td>
</tr>
<tr>
<td>Giglio, P</td>
<td>Open-Label, Phase 1/2 (Safety Lead-in) of TSC with Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed GBM Patients to Evaluate Safety and Efficacy INC Research, Inc. 100-202 (12111479)</td>
<td></td>
<td></td>
<td>$123,506</td>
</tr>
<tr>
<td>Halford, J</td>
<td>On-Line, Real-Time Seizure Prediction Optima Neuroscience, Inc. 1R43NS076045-01A1 (12111493)</td>
<td></td>
<td></td>
<td>$36,928</td>
</tr>
<tr>
<td>Jhou, T</td>
<td>Habenulomesencephalic Pathway in Aversion, Reward, and Depression Univ. of Maryland SROOOO21359/RO1 MH094489 (12010012)</td>
<td></td>
<td></td>
<td>$96,876</td>
</tr>
<tr>
<td>Kalivas, P</td>
<td>Neurobiology of Addiction Research Center (NARC) NIH/NIDA 5P50DA015369-10 (12081176)</td>
<td></td>
<td></td>
<td>$1,183,248</td>
</tr>
<tr>
<td>Kindy, M</td>
<td>Complement and Traumatic Brain Injury VAMC RX000331 (10051963)</td>
<td></td>
<td></td>
<td>$231,700</td>
</tr>
<tr>
<td>Mintzer, J</td>
<td>A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating CERE-110 Gene Delivery in Subjects with Mild to Moderate Alzheimer’s Disease Univ. of California, San Diego ADC-033/U01 AG10483 (10101948)</td>
<td></td>
<td></td>
<td>$500,625</td>
</tr>
<tr>
<td>Mintzer, J</td>
<td>ADCS Infrastructure Support Univ. of California, San Diego PO10323242/AG010483-21 (12101350)</td>
<td></td>
<td></td>
<td>$49,999</td>
</tr>
<tr>
<td>Mintzer, J</td>
<td>Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients with Mild to Moderate Alzheimer’s Disease Univ. of California, San Diego AG10483 (12101354)</td>
<td></td>
<td></td>
<td>$194,000</td>
</tr>
<tr>
<td>Turan, T</td>
<td>Characterization of Intracranial Atherosclerotic Stenosis Using HR MRI NIH/NINDS 5K23NS069668-02 (12091236)</td>
<td></td>
<td></td>
<td>$171,955</td>
</tr>
<tr>
<td>Turner, R</td>
<td>Work Order #3 - Codman Flow Diverter: Acute In-Vivo Feasibility Lab #1 Codman and Shurtleff, Inc. Work Order #3 (12111510)</td>
<td></td>
<td></td>
<td>$21,529</td>
</tr>
<tr>
<td>Turner, R</td>
<td>Axium MicroFx Coil Study - Project Agreement #1 Tyco Healthcare Group Project Agreement 1 (12111554)</td>
<td></td>
<td></td>
<td>$38,775</td>
</tr>
</tbody>
</table>
Resident and Fellow Update

**NEW NEUROLOGY RESIDENTS**

Datta, Mohit (PGY4)

Bazarsky, Ally (PGY-1)

Khouri, George (PGY-1)

Tsai, Michelle (Yi-Jou) (PGY-1)

Vanino, Dana (PGY-1)

Yamada, Lidia (PGY-1)

Callen, Megan (Psychology/Neurology - PGY1)

**NEUROLOGY FELLOWS**

Andrews, Charlie, M.D. (Neurocritical Care Fellow)

Bernard, Martine, M.D. (Clinical Neurophysiology Fellow)

Hanson, Jarom, M.D. (Clinical Neurophysiology Fellow)

Radauzo, Karen, M.D. (Clinical Neurophysiology Fellow)

de Leonni Stanonik, Mateja, M.D. (Vascular Fellow)

**NEW NEUROSURGERY RESIDENTS**

Zachary G. Wright, M.D.
PGY Level: 3
Medical School/Yr of Graduation: Columbia University, New York, New York (2010)
Clinical Interests: Pediatric neurosurgery, cerebrovascular neurosurgery, skull base
Research Interests: Neuroprosthetics, epilepsy, flow dynamics

Ryan T. Kellogg, M.D.
PGY Level: 1
Medical School/Yr of Graduation: Duke University School of Medicine, Durham, North Carolina (2012)
Clinical Interests: Cerebrovascular neurosurgery, skull base neurosurgery, endovascular neurosurgery
Research Interests: Endovascular neurosurgery, diagnostic imaging, and medical technology

**NEW PEDIATRIC NEUROLOGY RESIDENT**

Emma Carter, M.D.
Welcome New Employees

Ashley, Colette (Student/Other)
Athreya, Maddy (Student/MUSC)
Baker, Lauren (Volunteer)
Baranello, Robert (Grad Asst)
Barrett, Diana (Admin Asst)
Becker-Krail, Darius (Student/Other)
Bentzley, Brandon (Grad Asst/MSTP)
Bordineau, Bogdan (Volunteer)
Bowers, Terrell (Volunteer)
Breddlove, Jessica (RS I)
Brown, Robyn (Postdoc)
Brown, Kyle (TEMP, RS I)
Burnham, Nathan
Burris, Jessica (Postdoc)
Chopade, Pramod (Student/MUSC)
Clayton, Elyse (RS I)
Davis, Sheri (RS II)
Douglas, Amber (Volunteer)
Ellis, John (Student/Other)
Fisher, Jo Ann (Prog Mgr-Spch Path)
Freeman, Linnea (Postdoc)
Generous, Rochanya (Volunteer)
Gerlach, Christian (Vis Res Scholar)
Goforth, Melinda (Volunteer)
Gotshall, Alexandra (Prog Asst)
Gregory, Nicholas (RS II)
Gundran, Andrew (TEMP, RS I)
Helwig, Stephanie (Prog Coord)
Holsberg, Zachary (Volunteer)
Jessmore, Alex (Volunteer)
Kent, Kevin (Student/Other)
Lench, Daniel (Student/Other)
McCarthy, Jordan (Volunteer)
McIntock, Susan (Admin Asst)
Mahler, Stephen (Postdoc)
Motts, Andrew (Student/Other)
Narasimha Naidu, Kamalakkannan (Postdoc)
Paul, Matthew (Student/Other)
Peay, J. Celeste (Volunteer)
Podbielska, Maria (Short term scholar)
Ray, Raven (Volunteer)
Roberts, Donna (Dual Asst Prof)
Robinson, Sarah (Student/Other)
Rose, Joanne (RN II)
Smiley, Kyle (Student/Other)
Spencer, Sade (PD)
Szer, Rebecca (Volunteer)
Taylor, Zachary (RS I)

Goodbye and Good Luck

Tran, Sisi (Student/Other)
Voeks, Jennifer (Res Asst Prof)
Whig, Shalika (Student/MUSC)
Hinkson, Britt (PA)
Kalhorn, Stephen (Neurosurgery, MD)
Mirapuri, Amrendra (Neurosurgery, MD)
Bonilha, Leonardo (Neurology, MD, PhD)
Vaughan, Christina (Neurology, MD)
Ozark: Shelly D. (Neurology, MD)
Goodman, Diana (Neurosurgery, MD)
Armour, Joseph (Neurosurgery)
Spioita, Alejandro (Neurosurgery, MD)
Athreya, Madhura (Res Student)
Smiley, Kyle (Res Student)
Barrett, Diana (Admin Asst)
Brown, Mia (Admin Asst)
Bamford, Laura (ANP Neurology)
starts 8/20
Huffman, June (RN Ped Epilepsy)

Arapulismy, Obulakshmi (RS I)
Baik, Grace (Res Spec I)
Baranello, Robert (RS I)
Barnwell, Eliza (RSI)
Becker-Krail, Darius (Volunteer)
Benton, Erik (Stat & Res Analyst)
Bordineau, Bogdan (Volunteer)
Branton, Jennifer Godbee (PD)
Brewer, Ethan (Volunteer)
Brewer, Ethan (Student)
Brown, Kyle (volunteer)
Buhusi, Catalin (Assoc Prof)
Buhusi, Mona (Res Asst Prof)
Caskey, Michelle (Prog Asst)
Chan, Clifford (RS I)
Dasgupta, Subhajit (Staff Sci. I)
Dillon, Kelly (Program Assistant)
Do, Phong (RS I)
El Sayed, Hanaa (Staff Sci. I)
Etheredge, Chris (RS I)
Feltenstein, Matthew (Staff Sci. I)
Garry, Jennifer (RNII)
Gregory, Nicholas (RS I then RS II)
Hardin, Rebecca (Prog Coord I)
He, Hao (Olivia) (RS I)
Helwig, Stephanie (Admi Asst FTE)
Hill, Cody (Data Coord)
Hughes, Hannah (Student/Other)
Hunter, Clarence (Lab Aid)
Kitch, Alec (TEMP Data Coord.)
Knackstedt, Lori (Res Asst Prof)
Lench, Daniel (Volunteer)
Logothetis, K. Britt (RS I)
Madisetti, Mohan (Moby)
Maggoncaldia, Elise (TEMP RS I)
Malloy, Janice (Grants Admin II)
Mappus, Elliott (Student/Other)
Mason, Caroline (Public Info Coord)
Mason, Caroline (TEMP PT)
Mazzell, Cheryl (RS II)
McGonigal, Justin (Volunteer)
Minkin, Samantha (Prog Asst)
Morrison, Daniel (RS I)
Motts, Andrew (Student/Other)
Obert, Elisabeth (Student)
Oh, Eric (RS I)
Paddock, Linda (TEMP Admin Asst)
Petrella, Matthew (RS I)

Podbielska, Maria (Postdoc)
Pusser, Emily (Admin. Asst)
Robinson, Sarah (Volunteer)
Shen, Hao-wei (Res Asst Prof)
Shen, Zhiming (Postdoc)
Sigmon, Stacey (Res Spec I)
Tetrick, Lee Ann (Prog Asst)
Tompa, Tamas (Postdoc)
Tran, Phuong (Sisi) (Student/Other)
Waters, Parrish (Postdoc)
Watts, Amanda (RS I)
Watts, Jan Marie (RN II)
Wilson, Rebecca (RS I)
Yamada, Lidia (TEMP RS I)
Yang, John (RS I)

Lynch, Katrina (PA)
Destefano, Rhett (Neurology)
Warmath, William (Neurosurgery, MD)
Elizabeth Hamilton, NP was recently married. Her name is now Elizabeth Koontz, NP.

Lane Elsey, Epilepsy Data Coordinator was recently married and new name is Lane Stallworth.

**STARTING FROM TOP LEFT (GOING CLOCKWISE)**

**Dr. Robert Adams and friends at Titanic themed fundraising party** • **Participants at NI’s event Frontiers** • **Resident Jarom Hanson and his new baby boy Henrik** • **Dr. Patel, Neurosciences Co-chair, volunteering at the pie station during the Brain Tumor Action Fair** • **Mayor Swails and Dr. Greenberg at the Brain Tumor Action Fair** • **Resident Libby Kosnik’s baby boy Rhett** • **Dr. Samir Karia’s new baby girl**
Neurosciences Resources

Neurosciences offers a variety of resources for its faculty and staff including: medical illustration, animation, graphic design & web design: Free of charge!

Find out about your resources at
www.MUSC.edu/neurosciences/resources

Thank you for your contributions.
For questions, comments or to make a submission please contact:
Emma C. Vought at vought@musc.edu